$80K — $100K *
Ikena Oncology (NASDAQ: IKNA) is a clinical-stage, targeted oncology company that discovers and develops biomarker-driven therapies for cancer patients who need life-saving treatment, by understanding what drives their disease. Ikena is advancing five clinical, preclinical, and discovery programs and has a global strategic collaboration with Bristol Myers Squibb. Since inception, Ikena has raised over $300 million from leading life sciences investors and companies that include Atlas Venture, OrbiMed, BMS, Fidelity, Omega Funds, Surveyor Capital (a Citadel company), Invus, Farallon Capital Management, BVF Partners, Cowen Healthcare Investments, Logos Capital, and HealthCor Management. Ikena priced its IPO in March 2021 and trades on the NASDAQ (Ticker: IKNA).
The translational research group is looking for a talented and creative scientist who is passionate about oncology research that directly informs and shapes clinical trial designs. Areas of focus include patient selection strategy, sensitivity/resistance to agents targeting major oncogenic drivers and pathways, and rationale design of combination therapies. This individual will contribute and support multiple programs at late-stage discovery or development.
Personal attributes: team oriented, goal-driven, organized, highly collaborative, open-minded, data-driven, creative, persistent in the face of obstacles and uncertainty, flexible, self-aware of strengths and weaknesses, objective in the evaluation of data and strongly optimistic about overcoming challenges.
Valid through: 12/15/2021
$100K — $150K *
12 days ago